5 SIMPLE STATEMENTS ABOUT BREAST CANCER EXPLAINED

Genomic sequencing Evaluation of 733 HER2-amplified Most important and metastatic breast tumours exposed substantial enrichment of mutations that activate RAS–MAPK signalling in Superior tumours treated with prior anti-HER2 therapies121. These mutations, like NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib.What is